Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Bone loss after childhood acute lymphoblastic leukaemia: an observational study with and without GH therapy

Follin, Cecilia LU ; Link, Katarina LU ; Wiebe, Thomas LU ; Moëll, Christian LU ; Björk, Jonas LU and Erfurth, Eva Marie LU (2011) In European Journal of Endocrinology 164(5). p.695-703
Abstract
OBJECTIVE: Bone mineral density (BMD) in survivors of acute lymphoblastic leukaemia (ALL) seems to vary with time, type of treatments and GH status. We aimed to evaluate BMD in ALL patients with growth hormone deficiency (GHD), with and without GH therapy. DESIGN: Case-control study. METHODS: 44 (21 women) GHD patients (median 25 years), treated with cranial radiotherapy (18-24 Gy) and chemotherapy and matched population controls were examined for BMD with DXA (Dual-energy X-ray absorptiometry). Two subgroups; with (0.5 mg/day) (n=16) and without GH therapy (n=13), and matched controls, were followed for 5 and 8 years, respectively. RESULTS: At baseline, no significant differences in BMD or Z-scores at femoral neck and L2-L4 were recorded... (More)
OBJECTIVE: Bone mineral density (BMD) in survivors of acute lymphoblastic leukaemia (ALL) seems to vary with time, type of treatments and GH status. We aimed to evaluate BMD in ALL patients with growth hormone deficiency (GHD), with and without GH therapy. DESIGN: Case-control study. METHODS: 44 (21 women) GHD patients (median 25 years), treated with cranial radiotherapy (18-24 Gy) and chemotherapy and matched population controls were examined for BMD with DXA (Dual-energy X-ray absorptiometry). Two subgroups; with (0.5 mg/day) (n=16) and without GH therapy (n=13), and matched controls, were followed for 5 and 8 years, respectively. RESULTS: At baseline, no significant differences in BMD or Z-scores at femoral neck and L2-L4 were recorded (all P > 0.3). After another 8 years with GHD, Z-scores at femoral neck had decreased significantly compared to baseline (0.0 to -0.5; P<0.03), and became lower at femoral neck (P=0.05), and at L2-L4 (P<0.03), compared to controls. After 5 years of GH therapy only female ALL patients had a significantly lower femoral neck Z-scores (P=0.03). The female ALL patients reached an IGF-I level of -0.7 SD and in men the level was +0.05 SD. CONCLUSIONS: On average 25 years since diagnosis GH deficient ALL patients experienced a significant decrease in Z-scores at femoral neck and if Z-scores continuous to decrease there is a premature risk for osteoporosis. GH therapy was not shown to have a clear beneficial effect on BMD. Whether higher GH doses, particularly in women, will improve Z-scores needs further investigation. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Endocrinology
volume
164
issue
5
pages
695 - 703
publisher
Society of the European Journal of Endocrinology
external identifiers
  • wos:000289846200006
  • scopus:79955525983
  • pmid:21378089
ISSN
1479-683X
DOI
10.1530/EJE-10-1075
language
English
LU publication?
yes
id
27127f1f-40e8-437f-8cee-68f35b116d47 (old id 1884340)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21378089?dopt=Abstract
date added to LUP
2016-04-01 10:56:00
date last changed
2024-01-07 04:32:17
@article{27127f1f-40e8-437f-8cee-68f35b116d47,
  abstract     = {{OBJECTIVE: Bone mineral density (BMD) in survivors of acute lymphoblastic leukaemia (ALL) seems to vary with time, type of treatments and GH status. We aimed to evaluate BMD in ALL patients with growth hormone deficiency (GHD), with and without GH therapy. DESIGN: Case-control study. METHODS: 44 (21 women) GHD patients (median 25 years), treated with cranial radiotherapy (18-24 Gy) and chemotherapy and matched population controls were examined for BMD with DXA (Dual-energy X-ray absorptiometry). Two subgroups; with (0.5 mg/day) (n=16) and without GH therapy (n=13), and matched controls, were followed for 5 and 8 years, respectively. RESULTS: At baseline, no significant differences in BMD or Z-scores at femoral neck and L2-L4 were recorded (all P &gt; 0.3). After another 8 years with GHD, Z-scores at femoral neck had decreased significantly compared to baseline (0.0 to -0.5; P&lt;0.03), and became lower at femoral neck (P=0.05), and at L2-L4 (P&lt;0.03), compared to controls. After 5 years of GH therapy only female ALL patients had a significantly lower femoral neck Z-scores (P=0.03). The female ALL patients reached an IGF-I level of -0.7 SD and in men the level was +0.05 SD. CONCLUSIONS: On average 25 years since diagnosis GH deficient ALL patients experienced a significant decrease in Z-scores at femoral neck and if Z-scores continuous to decrease there is a premature risk for osteoporosis. GH therapy was not shown to have a clear beneficial effect on BMD. Whether higher GH doses, particularly in women, will improve Z-scores needs further investigation.}},
  author       = {{Follin, Cecilia and Link, Katarina and Wiebe, Thomas and Moëll, Christian and Björk, Jonas and Erfurth, Eva Marie}},
  issn         = {{1479-683X}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{695--703}},
  publisher    = {{Society of the European Journal of Endocrinology}},
  series       = {{European Journal of Endocrinology}},
  title        = {{Bone loss after childhood acute lymphoblastic leukaemia: an observational study with and without GH therapy}},
  url          = {{https://lup.lub.lu.se/search/files/2251846/1895139.pdf}},
  doi          = {{10.1530/EJE-10-1075}},
  volume       = {{164}},
  year         = {{2011}},
}